Given the observed associations between low-risk scores and a more immune-activated tumor microenvironment—characterized by higher infiltration of CD8+ T cells, NK cells, and M1 macrophages—these patients may be more likely to benefit from ICIs. This evidence concerns the gene CD8A and neoplasm.